Kisspeptin-10 — Research Dossier
Evidence grading
Receptor
KISS1R (GPR54)
On hypothalamic GnRH neurons
Position in HPG axis
Upstream of GnRH
Triggers GnRH pulse generation; acts above gonadorelin
Clinical lead form
Kisspeptin-54
Longer half-life; most Phase 1/2 data uses KP-54
FDA approval
None
Used under investigational protocols in UK reproductive endocrinology
Kisspeptin-10 is the minimal active fragment of kisspeptin and the furthest-upstream trigger of the reproductive hormone axis studied in humans — with genuine Phase 1/2 data from one concentrated research programme, where most evidence uses the longer kisspeptin-54 rather than the -10 fragment.
Kisspeptin is the product of the KISS1 gene (originally characterised as a metastasis-suppressor, hence the alternative name "metastin"). Kisspeptin-10 is the conserved C-terminal decapeptide — the minimal sequence that activates KISS1R (GPR54) on hypothalamic GnRH neurons. The reproductive role was established in 2003 when de Roux (Paris) and Seminara (Harvard) independently found that inactivating GPR54 mutations cause isolated hypogonadotropic hypogonadism.
Kisspeptin sits at the top of the HPG cascade: it drives GnRH release → pituitary LH/FSH → gonadal steroidogenesis. It is upstream of gonadorelin (synthetic GnRH) in this chain — where kisspeptin stimulates the GnRH neurons, gonadorelin is GnRH itself acting directly at the pituitary. The two are not interchangeable and act at different levels of the same axis.
“Intravenous kisspeptin-54 potently stimulated luteinising hormone, FSH, and testosterone in healthy men, placing kisspeptin at the apex of the hypothalamic-pituitary-gonadal cascade and opening a therapeutic target upstream of GnRH.”
— Dhillo WS et al., J Clin Endocrinol Metab 2005
Mechanism
Kisspeptin-10 binds KISS1R on GnRH neurons, increasing both the frequency and amplitude of LH pulses — modulating the fundamental rhythm of the HPG axis rather than simply amplifying output. The KISS1/neurokinin-B/dynorphin ("KNDy") network constitutes the molecular GnRH pulse generator, and kisspeptin is its key excitatory driver.
Self-limiting feature: continuous high-frequency KISS1R stimulation causes receptor desensitisation and paradoxical HPG suppression — the same principle exploited by GnRH-agonist downregulation. Pulsatile versus continuous stimulation produce opposite axis effects, as with gonadorelin.
Clinical evidence base
Human pharmacodynamics (established, mostly KP-54)
Dhillo et al. (2005, J Clin Endocrinol Metab) showed intravenous kisspeptin-54 potently stimulated LH, FSH, and testosterone in healthy men. The Imperial College London programme (Dhillo, Abbara, Jayasena) subsequently ran Phase 1/2 work including kisspeptin-54 as an IVF trigger with very low OHSS risk, and studies in hypothalamic amenorrhoea.
Kisspeptin-10 specifically
Direct human IV comparison of kisspeptin-10, kisspeptin-54, and GnRH (gonadorelin) on gonadotrophin secretion has been published (PMC4507333). KP-10 is the shorter-half-life fragment used where rapid clearance or pharmacokinetic control is an advantage; KP-54 is the lead clinical-development candidate. In subjects with idiopathic hypogonadotropic hypogonadism, KP-10 stimulates LH in some but not all patients, helping distinguish hypothalamic from pituitary-level defects.
Regulatory status
Not approved by the FDA, MHRA, or EMA for any indication. Kisspeptin-54 has been used under investigational protocols in UK reproductive-endocrinology trials. Distinct from gonadorelin (synthetic GnRH), which acts one level downstream at the pituitary. Material supplied for laboratory work is research-use-only.
Evidence grade: Phase I–II. A real human pharmacodynamic evidence base exists — stronger than many research peptides — but it is concentrated in one programme, weighted toward kisspeptin-54, and has not produced an approved indication or completed Phase III efficacy trial.
See also
References
- 1
de Roux N, et al. Hypogonadotropic hypogonadism due to loss of function of the KiSS1-derived peptide receptor GPR54 PNAS 2003.
- 2
Seminara SB, et al. The GPR54 gene as a regulator of puberty N Engl J Med 2003.
- 3
Dhillo WS, et al. Kisspeptin-54 stimulates the hypothalamic-pituitary-gonadal axis in human males J Clin Endocrinol Metab 2005. PMID: 16234306
- 4
Jayasena CN, Abbara A, et al. Kisspeptin-54 as an IVF trigger and in hypothalamic amenorrhoea — Imperial College London programme Clin Endocrinol 2013.
- 5
Dhillo WS, et al. Comparison of IV kisspeptin-10, kisspeptin-54 and GnRH on gonadotrophin secretion in healthy men Clin Endocrinol 2007. https://pmc.ncbi.nlm.nih.gov/articles/PMC4507333/
Research & Laboratory Use Only
This dossier is compiled for research planning and educational purposes only. It summarises published scientific literature and does not constitute medical advice, dosing guidance, or a therapeutic claim. All Nexyra Lab products are for research purposes only and are not for human or veterinary use. Nothing in this document should be interpreted as recommending, endorsing, or facilitating the self-administration of any compound.
A one-time legal review of this template and disclaimer is recommended before the Journal section is made publicly accessible, given the health-adjacent nature of this content.
